NM_024675.4:c.929G>A

Variant names:

Variant summary

Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM1BP4_ModerateBP6

The NM_024675.4(PALB2):c.929G>A(p.Ser310Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000682 in 1,613,916 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S310G) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000059 ( 0 hom., cov: 32)

Exomes 𝑓: 0.0000014 ( 0 hom. )

Consequence

PALB2
NM_024675.4 missense

Scores

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:6B:3

Conservation

PhyloP100: -0.0600

Publications

1 publications found

Variant links:

Genes affected

PALB2 (HGNC:26144): (partner and localizer of BRCA2) This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2. [provided by RefSeq, Jul 2008]

PALB2 Gene-Disease associations (from GenCC):

hereditary breast carcinoma
Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics
Fanconi anemia complementation group N
Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
pancreatic cancer, susceptibility to, 3
Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
familial ovarian cancer
Inheritance: AD Classification: MODERATE Submitted by: ClinGen
Fanconi anemia
Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
hereditary nonpolyposis colon cancer
Inheritance: AD Classification: LIMITED Submitted by: ClinGen

PALB2 links:

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -1 ACMG points.

PM1

In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 14 benign, 31 uncertain in NM_024675.4

BP4

Computational evidence support a benign effect (MetaRNN=0.0851078).

BP6

Variant 16-23635617-C-T is Benign according to our data. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762. Variant chr16-23635617-C-T is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 216762.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
PALB2	NM_024675.4 link	c.929G>A	p.Ser310Asn	missense_variant	Exon 4 of 13	ENST00000261584.9	NP_078951.2	Q86YC2

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
PALB2	ENST00000261584.9 link	c.929G>A	p.Ser310Asn	missense_variant	Exon 4 of 13	1	NM_024675.4	ENSP00000261584.4		Q86YC2

Frequencies

GnomAD3 genomes

AF:

0.0000592

AC:

AN:

152112

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.000193

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.0000655

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.00

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.00

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.00

Gnomad OTH

AF:

0.00

GnomAD2 exomes

AF:

0.00000796

AC:

AN:

251178

AF XY:

0.00

show subpopulations

Gnomad AFR exome

AF:

0.0000617

Gnomad AMR exome

AF:

0.0000289

Gnomad ASJ exome

AF:

0.00

Gnomad EAS exome

AF:

0.00

Gnomad FIN exome

AF:

0.00

Gnomad NFE exome

AF:

0.00

Gnomad OTH exome

AF:

0.00

GnomAD4 exome

AF:

0.00000137

AC:

AN:

1461804

Hom.:

Cov.:

AF XY:

0.00

AC XY:

AN XY:

727198

show subpopulations

African (AFR)

AF:

0.0000299

AC:

AN:

33474

American (AMR)

AF:

0.0000224

AC:

AN:

44720

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

26132

East Asian (EAS)

AF:

0.00

AC:

AN:

39686

South Asian (SAS)

AF:

0.00

AC:

AN:

86250

European-Finnish (FIN)

AF:

0.00

AC:

AN:

53414

Middle Eastern (MID)

AF:

0.00

AC:

AN:

5768

European-Non Finnish (NFE)

AF:

0.00

AC:

AN:

1111970

Other (OTH)

AF:

0.00

AC:

AN:

60390

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.500

Heterozygous variant carriers

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Age Distribution

Exome Het

Variant carriers

<30

30-35

35-40

40-45

45-50

50-55

55-60

60-65

65-70

70-75

75-80

>80

Age

GnomAD4 genome

AF:

0.0000592

AC:

AN:

152112

Hom.:

Cov.:

AF XY:

0.0000673

AC XY:

AN XY:

74324

show subpopulations

African (AFR)

AF:

0.000193

AC:

AN:

41418

American (AMR)

AF:

0.0000655

AC:

AN:

15268

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

3470

East Asian (EAS)

AF:

0.00

AC:

AN:

5204

South Asian (SAS)

AF:

0.00

AC:

AN:

4828

European-Finnish (FIN)

AF:

0.00

AC:

AN:

10598

Middle Eastern (MID)

AF:

0.00

AC:

AN:

316

European-Non Finnish (NFE)

AF:

0.00

AC:

AN:

68008

Other (OTH)

AF:

0.00

AC:

AN:

2092

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.503

Heterozygous variant carriers

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Age Distribution

Genome Het

Variant carriers

<30

30-35

35-40

40-45

45-50

50-55

55-60

60-65

65-70

70-75

75-80

>80

Age

Alfa

AF:

0.00

Hom.:

Bravo

AF:

0.0000453

ESP6500AA

AF:

0.000228

AC:

ESP6500EA

AF:

0.00

AC:

ExAC

AF:

0.00000824

AC:

ClinVar

Significance: Conflicting classifications of pathogenicity

Submissions summary: Uncertain:6Benign:3

Revision: criteria provided, conflicting classifications

LINK: link

Submissions by phenotype

Familial cancer of breast

Uncertain:1Benign:2

Jul 27, 2023

St. Jude Molecular Pathology, St. Jude Children's Research Hospital

Significance:Uncertain significance

Review Status:criteria provided, single submitter

Collection Method:clinical testing

The PALB2 c.929G>A (p.Ser310Asn) missense change has a maximum subpopulation frequency of 0.0080% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. This variant is absent in a database of women older than 70 years of age who have never had cancer (FLOSSIES, https://whi.color.com/) To our knowledge, this variant has not been reported in individuals with a personal and/or family history of breast and/or ovarian cancer or in individuals with Fanconi anemia. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. -

Nov 19, 2024

Labcorp Genetics (formerly Invitae), Labcorp

Significance:Likely benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Jan 13, 2025

Myriad Genetics, Inc.

Significance:Likely benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -

not provided

Uncertain:2

Nov 25, 2020

Quest Diagnostics Nichols Institute San Juan Capistrano

Significance:Uncertain significance

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Oct 28, 2024

GeneDx

Significance:Uncertain significance

Review Status:criteria provided, single submitter

Collection Method:clinical testing

Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 19369211) -

Hereditary cancer-predisposing syndrome

Uncertain:1Benign:1

May 31, 2024

Ambry Genetics

Significance:Likely benign

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Apr 03, 2023

Color Diagnostics, LLC DBA Color Health

Significance:Uncertain significance

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This missense variant replaces serine with asparagine at codon 310 of the PALB2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 3/282550 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -

not specified

Uncertain:1

May 24, 2024

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

Significance:Uncertain significance

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

PALB2-related disorder

Uncertain:1

Apr 25, 2024

PreventionGenetics, part of Exact Sciences

Significance:Uncertain significance

Review Status:no assertion criteria provided

Collection Method:clinical testing

The PALB2 c.929G>A variant is predicted to result in the amino acid substitution p.Ser310Asn. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0080% of alleles in individuals of African descent in gnomAD. Other variant at this codon p.Ser310Gly has been reported in an individual with breast cancer and an individual with melanoma (Table S3, Pritchard et al. 2018. PubMed ID: 29641532; Supplement, Tung et al. 2015. PubMed ID: 25186627) and it has also been reported in cases and controls from an ovarian cancer cohort study (Ramus et al. 2015. PubMed ID: 26315354). The p.Ser310Asn variant is interpreted as uncertain significance by the majority of submitters in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/216762/). At this time, the clinical significance of p.Ser310Asn variant is uncertain due to the absence of conclusive functional and genetic evidence. -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

AlphaMissense

Benign

0.10

BayesDel_addAF

Benign

-0.51

BayesDel_noAF

Benign

-0.79

CADD

Benign

4.7

(source)

DANN

Benign

0.92

DEOGEN2

Benign

0.022

T;T

Eigen

Benign

-0.86

Eigen_PC

Benign

-0.87

FATHMM_MKL

Benign

0.099

LIST_S2

Benign

0.69

T;T

M_CAP

Benign

0.020

MetaRNN

Benign

0.085

T;T

MetaSVM

Benign

-1.0

MutationAssessor

Benign

1.1

.;L

PhyloP100

-0.060

PrimateAI

Benign

0.28

PROVEAN

Benign

-0.55

N;N

REVEL

Benign

0.046

Sift

Uncertain

0.0090

D;T

Sift4G

Uncertain

0.018

D;T

Polyphen

0.010

.;B

Vest4

0.099

MVP

0.34

MPC

0.053

ClinPred

0.033

GERP RS

2.8

Varity_R

0.050

gMVP

0.17

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.0

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

Publications

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

Age Distribution

Age Distribution

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

Other links and lift over